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Abstract
Background: Tuberculosis (TB) now ranks alongside HIV as the leading infectious disease cause of death worldwide
and incurs a global economic burden of over $12 billion annually. Directly observed therapy (DOT) recommends
that TB patients complete the course of treatment under direct observation of a treatment supporter who is trained
and overseen by health services to ensure that patients take their drugs as scheduled. Though the current WHO
End TB Strategy does not mention DOT, only “supportive treatment supervision by treatment partners”, many TB
programs still use it despite the fact that the has not been demonstrated to be statistically significantly superior to
self-administered treatment in ensuring treatment success or cure.
Discussion: DOT is designed to promote proper adherence to the full course of drug therapy in order to improve
patient outcomes and prevent the development of drug resistance. Yet over 8 billion dollars is spent on TB
treatment each year and thousands undergo DOT for all or part of their course of treatment, despite the absence
of rigorous evidence supporting the superior effectiveness of DOT over self-administration for achieving drug
susceptible TB (DS-TB) cure. Moreover, the DOT component burdens patients with financial and opportunity costs,
and the potential for intensified stigma.
To rigorously evaluate the effectiveness of DOT and identify the essential contributors to both successful treatment
and minimized patient burden, we call for a pragmatic experimental trial conducted in real-world program settings,
the gold standard for evidence-based health policy decisions. It is time to invest in the rigorous evaluation of DOT
and reevaluate the DOT requirement for TB treatment worldwide.
Summary: Rigorously evaluating the choice of treatment supporter, the frequency of health care worker contact
and the development of new educational materials in a real-world setting would build the evidence base to
inform the optimal design of TB treatment protocol. Implementing a more patient-centered approach may be a wise
reallocation of resources to raise TB cure rates, prevent relapse, and minimize the emergence of drug resistance.
Maintaining the status quo in the absence of rigorous supportive evidence may diminish the effectiveness of TB control
policies in the long run.
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Background
Tuberculosis (TB) now ranks alongside HIV as the lead-
ing infectious disease cause of death worldwide and in-
curs a global economic burden of more than $12 billion
annually [1]. In 2014, approximately 9.6 million people
contracted TB globally and 1.5 million died from the
disease [1]. Directly observed therapy (DOT), based on
standardized TB treatment with supervision and patient
support, was pioneered in the 1970s and was a core
component of the World Health Organization (WHO)
TB strategy from 1996 to 2015 [2]. Though the current
WHO End TB Strategy does not mention DOT but ra-
ther “supportive treatment supervision by treatment
partners”, many TB programs still use DOT despite the
fact that the has not been demonstrated to be statisti-
cally significantly superior to self-administered treatment
in ensuring treatment success or cure [3].
The DOT component, which accounts for up to 75 %
of the provider costs of TB treatment [4], recommends
that patients complete the course of treatment under
direct observation of a treatment partner or supporter
who is trained and overseen by health services to ensure
that patients take their drugs as scheduled [2]. DOT is
designed to promote proper adherence to the full course
of drug therapy in order to improve patient outcomes
and prevent the development of drug resistance. Yet
over 8 billion dollars is spent on TB treatment each year
[1] and thousands undergo DOT for all or part of their
course of treatment, despite the absence of rigorous
evidence supporting the superior effectiveness of DOT
over self-administration for achieving drug susceptible
TB (DS-TB) cure [5–8]. Moreover, the DOT component
burdens patients with financial and opportunity costs,
and the potential for intensified stigma [4, 9, 10].
Thus, the effectiveness of DOT for DS-TB should be
rigorously evaluated relative to less burdensome alterna-
tive treatment protocols with a pragmatic experimental
trial conducted in real-world program settings, the gold
standard foundation for evidence-based health policy de-
cisions. Self-administration could prove to be not only
as effective as DOT in curing TB, preventing relapse and
minimizing the emergence of drug resistance, but also
more cost-effective, because it is generally less expensive
than health-center-based DOT [4]. Self-administration
could therefore relieve the burden on TB patients
while increasing cost-effectiveness and protecting public
health. Considering the overall financial and human cost
of TB and the clinical equipoise of DOT, the relative cost
of an experimental evaluation of the effectiveness of DOT
would be a wise investment of limited funds.
Between 1995 and 2012, an estimated 56 million indi-
viduals were successfully treated for tuberculosis under
the DOTS/Stop TB strategy in 184 countries [11]. World-
wide, approximately 86 % of TB patients successfully
complete treatment; however, treatment success and cure
rates vary widely by geographic region and per capita in-
come and TB cure rates may be substantially lower than
treatment success rates [1]. Considering the worldwide
17 % case fatality rate and cure rates as low as 69 % in
Russia and 72 % in Brazil [1], it is imperative that TB
treatment protocols be subject to rigorous evaluation of
their effectiveness in curing DS-TB, preventing relapse
and minimizing the emergence of drug resistance.
The burden of direct observation
The financial and psychosocial burden of DOT on pa-
tients can be substantial, even when national TB pro-
grams provide drugs at no direct cost to the patient [4].
In DOT programs requiring patients to make multiple
clinic (or community center) visits per week, patients
may incur significant monetary and time costs of travel
if reimbursements or subsidies to offset these costs are
not provided [12]. Over the course of 6 or more months
of TB treatment these costs add up. Although some TB
treatment programs have health workers conduct DOT
in patients’ homes rather than health facilities, no official
numbers exist on how many programs administer TB
treatment through this method [1]. Aside from direct
costs, frequent visits to health facilities for DOT may
interfere with a patient’s work schedule or home produc-
tion responsibilities (such as child care), lead to lost
wages, or cause the loss of employment [12]. In addition,
frequent visits to TB treatment facilities or from DOT
health workers may intensify the stigma associated with
TB and diminish a patient’s ability to maintain privacy
about their health [9]. Fear of stigma and the burden of
DOT may prevent patients from completing TB treat-
ment, or seeking TB testing in the first place [9].
Limited high-quality evidence of DOT
effectiveness
In reviewing the recent literature on DOT in developing
countries we find that there is a very limited high-
quality evidence demonstrating that DOT is more effect-
ive than self-administration at achieving DS-TB cure.
We identified four systematic reviews [5–8] that com-
pared DOT to self-administration. Among these reviews,
Tian et al. [6] found no convincing evidence that DOT
achieves statistically significantly higher treatment suc-
cess or cure rates than self-administration when the two
regimens were compared in four randomized controlled
trials (RCTs). Data from eight observational studies sug-
gested DOT to be more effective, however, these non-
randomized studies do not adequately address concerns
about confoundedness [6]. Pasipanodya & Gumbo’s [5]
meta-analysis of five RCTs and five observational studies
demonstrated that DOT was no more effective at pre-
venting treatment failure than self-administration. One
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systematic review [8] concluded that DOT improved
treatment success and cure rates based on results from
one RCT and two quasi-experimental studies. Of the six
RCTs examined by Karumbi & Garner [7], only one add-
itional study found higher cure and treatment completion
rates among patients enrolled in DOT when compared to
self-administration. Based on the preponderance of high-
quality RCT evidence, we echo the conclusions from
systematic reviews finding that the evidence provides
“no assurance that DOT compared with self-administration
of treatment has any quantitatively important effect on
cure or treatment completion” [13].
A call for rigorous evaluation of DOT
To rigorously evaluate the effectiveness of DOT and
identify the essential contributors to both successful
treatment and minimized patient burden, we call for a
pragmatic experimental trial conducted in real-world
program settings. Experimental trials have frequently
been used to guide and evaluate public health interven-
tions such as the effect of immediate initiation of ART
treatment for HIV patients [14], a pre-eclampsia inter-
vention on maternal mortality [15] and deworming on
school attendance [16]. The experimental evaluation
should be conducted in a pragmatic setting with organi-
zations already providing TB treatment and monitoring
outcomes in order to mimic a real-world policy change,
improve the generalizability of results and minimize the
Hawthorne effect. To minimize any contamination of the
control group, facilities (rather than individual patients)
could be randomized to DOT vs. self-administration.
Because DOT imposes greater costs on providers
and patients, demonstrating the non-inferiority of self-
administration relative to DOT is sufficient to motivate
changes in TB program treatment protocol.
Each aspect of TB treatment should be designed to cure
TB, prevent relapse, and minimize the emergence of drug
resistance in the most effective and cost-effective way pos-
sible. Rigorously evaluating one or more of the following
components in a real-world setting would build the evi-
dence base to inform the optimal design of the TB treat-
ment program. First, TB patients could self-administer
treatment under supervision of a health care worker or
use an alternative DOT observer such as a community
leader [6]. Family members are unlikely to be the ideal ob-
servers. This could increase patient autonomy and self-
efficacy while minimizing the need for frequent health
facility visits. Second, an evaluation could establish the
optimal frequency of health care worker visits to provide
necessary patient support, screen for side effects and
promptly identify barriers to adherence, while minimizing
the burden on patients [17]. Third, patient and peer sup-
port groups could improve patient education and provide
support for adherence and treatment completion [18].
Fourth, the development of patient-centered training and
educational materials could increase patient treatment
literacy for self-administering treatment. Finally, a focus on
patient-centered delivery of treatment could improve out-
comes for all TB patients. DOT proponents have argued
that requiring DOT is necessary to promote early detec-
tion of treatment failure and engender effective patient-
provider communication [19]. However, neither of these
goals require DOT, and can be achieved with self-
administration or alternative versions of TB treatment.
Ideally, a series of rigorous RCTs, conducted in multiple
countries and in a variety of operational settings, would
evaluate these components and build a robust evidence
base for TB policy and practice. These studies could also
be accompanied by a rigorous costing analysis.
Conclusion
Some proponents of direct observation have argued that
altering TB treatment, such as allowing deviations from
DOT, is a “slippery slope” that will ultimately lead to an
erosion of support for TB control and a reduction in
quality of care [20]. However, the design of TB programs
must remain responsive to new developments in the epi-
demic and the evidence base. It is time to invest in the
rigorous evaluation of DOT to determine whether the
additional cost of this practice is justified by improved
outcomes for TB patients worldwide. We call upon the
implementing community to affirm its commitment to
evidence-based policy making and upon the research
community to produce high-quality evidence to support
these critical decisions. Maintaining the status quo in
the absence of rigorous supportive evidence may dimin-
ish the effectiveness of TB control in the long run.
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